Views & Analysis Q&A: Fortress Biotech’s Lindsay Rosenwald on breathing new l... One downside of the explosion in our knowledge about potential drug targets is that many promising candidates are getting left on the backburner.
News Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face